Abstract:Purpose To explore the relationship between rs2291075 polymorphism in SLCO1B1 gene, which encodes an influx transmembrane protein transporter, and tacrolimus dose–corrected trough concentration (C/D, ng ml −1 mg −1 kg −1 ) in the early period after liver transplantation. Methods CYP3A5 rs776746 and SLCO1B1 rs2291075 polymorphisms of 210 liver transplantation patients and their corresponding donor livers were assessed by PCR amplification and DNA sequencing. The influence of gene polymorphisms on C/D values of tacrolimus was analyzed. The early postoperative period after liver transplantation was divided into the convalescence phase (1–14 days) and stationary phase (15–28 days) according to the change of liver function and tacrolimus C/D values. Results The combined analysis of donor and recipient CYP3A5 rs776746 could distinguish the metabolic phenotype of tacrolimus into three groups: fast elimination (FE), intermediate elimination (IE), and slow elimination (SE), which was entitled the FIS classification system. Tacrolimus C/D ratios of recipient SLCO1B1 rs2291075 CT and TT carriers were very close and were significantly lower than those of recipient SLCO1B1 rs2291075 CC genotype carriers in convalescence phase ( p = 0.0195) and in stationary phase ( p = 0.0152). There were no statistically significant differences between tacrolimus C/D ratios of patients carried with SLCO1B1 rs2291075 CT, TT genotype donors, and those carried with SLCO1B1 rs2291075 CC genotype donors. A model consisting of tacrolimus daily dose, total bilirubin, FIS classification, and recipient SLCO1B1 rs2291075 could predict tacrolimus C/D ratios in the convalescence phase by multivariate analysis. However, recipient SLCO1B1 rs2291075 genotype failed to enter forecast model for C/D ratios in stationary phase. Recipient SLCO1B1 rs2291075 genotype had significant effect on tacrolimus C/D ratios in convalescence phase ( p = 0.0300) and stationary phase ( p = 0.0400) in subgroup, which excluded the interference come from donor and recipient CYP3A5 rs776746. Conclusion SLCO1B1 rs2291075 could be a novel genetic locus associated with tacrolimus metabolism. The combined analysis of donor and recipient CYP3A5 rs776746, recipient SLCO1B1 rs2291075 genotypes, could be helpful to guide the personalized administration of tacrolimus in early period after liver transplantation.

Donor Il-18 Rs5744247 Polymorphism As A New Biomarker Of Tacrolimus Elimination In Chinese Liver Transplant Patients During The Early Post-Transplantation Period: Results From Two Cohort Studies

Influence of IL-18 and IL-10 Polymorphisms on Tacrolimus Elimination in Chinese Lung Transplant Patients

Association of Donor Cytochrome P450 3A Family Polypeptide 5 and Interleulin-18 Polymorphisms with the Individual Dosage Regimen of Tacrolimns in Chinese Liver Transplantation Recipients

Influence of TLR4 Rs1927907 Locus Polymorphisms on Tacrolimus Pharmacokinetics in the Early Stage after Liver Transplantation

Novel Single Nucleotide Polymorphisms in Interleukin 6 Affect Tacrolimus Metabolism in Liver Transplant Patients.

Population Pharmacokinetics of Tacrolimus and CYP3A5, MDR1 and IL-10 Polymorphisms in Adult Liver Transplant Patients

Polymorphisms of Tumor Necrosis Factor-Α, Interleukin-10, Cytochrome P450 3A5 and ABCB1 in Chinese Liver Transplant Patients Treated with Immunosuppressant Tacrolimus

Impact of Interleukin-10 Gene Polymorphisms on Tacrolimus Dosing Requirements in Chinese Liver Transplant Patients During the Early Posttransplantation Period.

CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.

The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose–corrected trough concentration in the early period after liver transplantation

Association Between Interleukin-18 Promoter Variants and Tacrolimus Pharmacokinetics in Chinese Renal Transplant Patients

Combined Effect of Donor Cytochrome P450 3A Family Polypeptide 5 and Recipient Cytochrome P450 3A Family Polypeptide 4 Polymorphisms on the Individual Dosage Regimen of Tacrolimus in Chinese Liver Transplant Patients

Association of CYP3A5 and IL-10 Polymorphisms with the Individual Dosage Regimen of Tacrolimus in Lung Transplantation Recipients

Impact of genetic polymorphisms on tacrolimus concentrations and intra-individual variability in recipients of heart transplants during the early post-heart transplantation period

Donors FMO3 polymorphisms affect tacrolimus elimination in Chinese liver transplant patients.

Association of Hemoglobin Levels, CYP3A5, and NR1I3 Gene Polymorphisms with Tacrolimus Pharmacokinetics in Liver Transplant Patients

Association of Donor Small Ubiquitin-Like Modifier 4 Rs237025 Genetic Variant with Tacrolimus Elimination in the Early Period after Liver Transplantation.

Association of CYP3A5 and C5 Polymorphisms with the Individual Dosage Regimen of Tacrolimus in Chinese Liver Transplantation Recipients During the Early Post-Transplantation Period

IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients

The Association Between Interleukin-6 Rsl800796 Locus Single Nucleotide Polymorphisms in the Donors and Recipients and Concentration/dose Ratios of Tacrolimus after Liver Transplantation

Stepwise Regression Analysis of the Determinants of Blood Tacrolimus Concentrations in Chinese Patients with Liver Transplant